Cargando…
High-throughput approaches for precision medicine in high-grade serous ovarian cancer
High-grade serous carcinoma (HGSC) is the most prevalent and aggressive subtype of ovarian cancer. The large degree of clinical heterogeneity within HGSC has justified deviations from the traditional one-size-fits-all clinical management approach. However, the majority of HGSC patients still relapse...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7547483/ https://www.ncbi.nlm.nih.gov/pubmed/33036656 http://dx.doi.org/10.1186/s13045-020-00971-6 |
_version_ | 1783592430468071424 |
---|---|
author | Govindarajan, Meinusha Wohlmuth, Christoph Waas, Matthew Bernardini, Marcus Q. Kislinger, Thomas |
author_facet | Govindarajan, Meinusha Wohlmuth, Christoph Waas, Matthew Bernardini, Marcus Q. Kislinger, Thomas |
author_sort | Govindarajan, Meinusha |
collection | PubMed |
description | High-grade serous carcinoma (HGSC) is the most prevalent and aggressive subtype of ovarian cancer. The large degree of clinical heterogeneity within HGSC has justified deviations from the traditional one-size-fits-all clinical management approach. However, the majority of HGSC patients still relapse with chemo-resistant cancer and eventually succumb to their disease, evidence that further work is needed to improve patient outcomes. Advancements in high-throughput technologies have enabled novel insights into biological complexity, offering a large potential for informing precision medicine efforts. Here, we review the current landscape of clinical management for HGSC and highlight applications of high-throughput biological approaches for molecular subtyping and the discovery of putative blood-based biomarkers and novel therapeutic targets. Additionally, we present recent improvements in model systems and discuss how their intersection with high-throughput platforms and technological advancements is positioned to accelerate the realization of precision medicine in HGSC. |
format | Online Article Text |
id | pubmed-7547483 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-75474832020-10-13 High-throughput approaches for precision medicine in high-grade serous ovarian cancer Govindarajan, Meinusha Wohlmuth, Christoph Waas, Matthew Bernardini, Marcus Q. Kislinger, Thomas J Hematol Oncol Review High-grade serous carcinoma (HGSC) is the most prevalent and aggressive subtype of ovarian cancer. The large degree of clinical heterogeneity within HGSC has justified deviations from the traditional one-size-fits-all clinical management approach. However, the majority of HGSC patients still relapse with chemo-resistant cancer and eventually succumb to their disease, evidence that further work is needed to improve patient outcomes. Advancements in high-throughput technologies have enabled novel insights into biological complexity, offering a large potential for informing precision medicine efforts. Here, we review the current landscape of clinical management for HGSC and highlight applications of high-throughput biological approaches for molecular subtyping and the discovery of putative blood-based biomarkers and novel therapeutic targets. Additionally, we present recent improvements in model systems and discuss how their intersection with high-throughput platforms and technological advancements is positioned to accelerate the realization of precision medicine in HGSC. BioMed Central 2020-10-09 /pmc/articles/PMC7547483/ /pubmed/33036656 http://dx.doi.org/10.1186/s13045-020-00971-6 Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Review Govindarajan, Meinusha Wohlmuth, Christoph Waas, Matthew Bernardini, Marcus Q. Kislinger, Thomas High-throughput approaches for precision medicine in high-grade serous ovarian cancer |
title | High-throughput approaches for precision medicine in high-grade serous ovarian cancer |
title_full | High-throughput approaches for precision medicine in high-grade serous ovarian cancer |
title_fullStr | High-throughput approaches for precision medicine in high-grade serous ovarian cancer |
title_full_unstemmed | High-throughput approaches for precision medicine in high-grade serous ovarian cancer |
title_short | High-throughput approaches for precision medicine in high-grade serous ovarian cancer |
title_sort | high-throughput approaches for precision medicine in high-grade serous ovarian cancer |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7547483/ https://www.ncbi.nlm.nih.gov/pubmed/33036656 http://dx.doi.org/10.1186/s13045-020-00971-6 |
work_keys_str_mv | AT govindarajanmeinusha highthroughputapproachesforprecisionmedicineinhighgradeserousovariancancer AT wohlmuthchristoph highthroughputapproachesforprecisionmedicineinhighgradeserousovariancancer AT waasmatthew highthroughputapproachesforprecisionmedicineinhighgradeserousovariancancer AT bernardinimarcusq highthroughputapproachesforprecisionmedicineinhighgradeserousovariancancer AT kislingerthomas highthroughputapproachesforprecisionmedicineinhighgradeserousovariancancer |